Physician profile
Danielle Parker
NPI 1306434824
$6,651.97
in general payments reported to CMS, 2019-2025
25 companies · $2,870 in 2025
The $2,870 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $528 · 2022: $1,313 · 2023: $1,035 · 2024: $907 · 2025: $2,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708 · Travel and Lodging: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,707.62 |
| Travel and Lodging | $1,103.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,772.09 | 2025 | Linq II |
| Boston Scientific Corporation | $885.38 | 2021-2023 | Watchman Access System |
| Amgen INC. | $567.11 | 2021-2025 | Repatha, Repatha |
| Cvrx, INC. | $499.06 | 2023-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $421.57 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $332.12 | 2022-2023 | Optimizer |
| Heartflow, INC. | $325.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $275.20 | 2023-2025 | Andexxa, Lokelma, Wainua |
| E.R. Squibb & Sons, L.L.C. | $239.58 | 2021-2025 | Eliquis |
| Edwards Lifesciences Corporation | $192.86 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Evoque |
| Bridgebio Pharma, INC. | $188.38 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $174.99 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $154.40 | 2022 | |
| Lilly USA, LLC | $140.00 | 2024 | Zepbound |
| Inspire Medical Systems, INC. | $118.51 | 2023-2024 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $90.49 | 2025 | |
| Pfizer INC. | $70.55 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $46.75 | 2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.48 | 2022-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.54 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.95 | 2024 | |
| Ge Healthcare | $17.63 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.39 | 2022 | |
| Abbott Laboratories | $15.49 | 2024 | Ensite |
| Atricure, INC. | $14.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.